Abacavir hypersensitivity
Download as PPTX, PDF1 like804 views
This document summarizes a study investigating genetic markers associated with abacavir hypersensitivity. The study found that a combination of the HLA-B*5701 allele and a haplotypic variant of the Hsp70-Hom gene with a methionine to threonine change at amino acid position 493 were highly predictive of abacavir hypersensitivity. Patients with these genetic factors showed higher expression of the inflammatory cytokine TNF in response to abacavir stimulation, driven primarily by CD8 T cells. These genetic markers can help identify individuals at high risk of hypersensitivity reaction to abacavir.
Abacavir hypersensitivity
- 1. Rajina Shakya Department of Toxicology
- 2. • Nucleoside analogue • Potent anti-viral activity against HIV • Main side-effcet : Hypersensitivity include fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhea, or abdominal pain), and lethargy or malaise. ABACAVIR
- 3. HYPERSENSITIVITY Set of undesirable reactions produced by the normal immune system, including allergies and autoimmunity. These reactions may be damaging, uncomfortable, or occasionally fatal. Approximately, 5–9% of patients treated with abacavir developed hyper-sensitivity reaction. Symptoms usually appear within the first 6 weeks of treatment and worsen with continued therapy and improve within 72 h of abacavir discontinuation. Rechallenging, with abacavir after a hypersensitivity reaction typically results in recurrence of symptoms within hours, with the potential to induce a more severe clinical syndrome.
- 4. ABACAVIR HYPERSENSITIVITY • The susceptibility loci associated with abacavir hypersensitivity was further investigated by using recombinant AH mapping, within the central non-human leukocyte antigen (HLA) region of the MHC. • Combination of HLA-B*5701 and a haplotypic polymorphism of Hsp70- Hom is highly predictive of abacavir hypersensitivity, which provides the mechanistic basis of the hypersensitivity syndrome.
- 5. MATERIALSAND METHODS • Retrospective study N=200 • Prospective study N=48 Demographic data: Origin Total Patients (N=248) European or Asain Indian Descent 214 African 11 Austratians 15 Asian 8
- 6. Cases Observed patients Abacavir Hypersensitive 18 Abacavir Hypersensitive not excluded 15 Abacavir tolerant individual 215 CLASSIFICATION OFHYPERSENSITIVITYCASES
- 7. PATCH TEST Cases Case observed Patch test Abacavir Hypersensitive W 57.1 AH 14 9 W/o 57.1 AH 4 3 Abacavir Hypersensitive not excluded 15 3 Abacavir tolerant individual (W57.1 AH) HLA-B*5701 alleles 2 Full 57.1AH (HLA-B*5701, C4A6, AND HLA-DRB1*0701,HLA-DQ3) 2 • 24 and 48 h of application • Absence of an allergic response for positive results
- 8. Typing of MHC Markers andAssignment ofAlleles Specific to the 57.1AH • Carried out by using standard genetic assays and sequencing. • Single-nucleotide polymorphisms (SNPs) within genes located in the C4A6–MEGT1 region were examined by using the SNP database. • Primers were designed based on oligonucleotide sequences reported within the database. • A set of well characterized Epstein–Barr virus-transformed homozygous B cell lines representing commonly occurring European AHs was used to determine alleles carried on the 57.1 AH. • Full-length sequencing across the Hsp70 gene cluster was performed by using overlapping primer pairs.
- 9. Measurement of the TNF Response to Abacavir • Intracellular expression of TNF was assessed in cultured peripheral blood mononuclear cells (PBMCs) grown in the presence and absence of abacavir(Ziagen 300-mg). • The PBMCs were stained with CD45-ECD, CD14-FITC, or IgG1- FITC antibodies and analyzed on flow cytometer. CD4 and CD8 Cell Depletion. • TNF levels were measured in supernatants of 1ml of whole blood cultured in the absence and presence of abacavir (1 g/ml) for 24 h at 37°C. • Whole blood was depleted of either CD4 or CD8 T cells.
- 10. RESULTS 200 participants from retrospective study Clinically Abacavir Hypersensitivity case N=18 N=3 (receiving nevirapine therapy) : negative response to patch test after 48 hrs of application N=2 rechallenged successfully with abacavir w/o developing ABC hypersensitivity Meanwhile, third patient developed similar hypersensitivity reaction to efavirenz
- 11. RESULTS Another retrospective cohort case “abacavir hype rsensitivity not excluded” Typical and severe symptoms Received clinical diagnosis within a few days of exposure to abacavir and received intensive supportive inpatient care at a hospital No symptoms were identified Also, Individual more likely to be desensitized by the continued administration of abacavir,Negative response to epicutaneous patch testing
- 14. Mapping of Putative Susceptibility Loci Within the MHC • Markers of 57.1 AH, within the central MHC region, between C4A6 and MEGT1were identified. • Hsp70 cluster between MEGT1 and snRNP was compared with the sequence of 8.1, 7.1, and 18.2 AHs but nonsynonymous substitutions was not identified. • The only nucleotide substitution in the Hsp70- Hom gene identified in most of the abacavir-hypersensitive cases involved a T to C transition, which results in a change from methionine to threonine at amino acid residue. • The Hsp70-Hom M493T allele on 57.1 AH, was detected to be 94.4% of the hypersensitive group compared with 22.2% of tolerant controls (17 of 18 individuals vs. 51 of 230 individuals, OR 59.7, Pc 0.00001). • In combination with HLA-B*5701, the Hsp70-Hom M493T allele was strongly associated with abacavir hypersensitivity.
- 16. Expression of Inflammatory Cytokine TNFin Abacavir-Hypersensitive Individuals • Cytokine response was examined by measuring intracellular TNF levels in cultures of PBMCs from abacavir-hypersensitive, -tolerant, and unexposed HIV-positive patients. • The proportion of TNF-positive cells was higher in patients with abacavir hypersensitivity (n =8) than in abacavir-tolerant controls (n=9) compared with decrease in tolerant controls. • The three individuals classified as abacavir-tolerant on the basis of a negative epicutaneous patch test also had no increase in TNF-positive cells in response to abacavir stimulation.
- 17. Phenotype of T Cells Expressing TNFAfter Abacavir Stimulation • Further phenotypic characterization of the T cell response to abacavir as carried out on whole blood cultures of two patients who were selected for analysis because they both carried the predictive HLA-B*5701 and Hsp70-Hom M493T alleles yet were divergent in their clinical responses to abacavir. • Definite abacavir hypersensitivity occurred in case 17 within 1 week of drug exposure, whereas case 21 tolerated this drug without any clinical symptoms suggestive of hypersensitivity. • Involvement of CD4 and CD8 T cells in the secretion of TNF in culture supernatants was determined after stimulation with abacavir. • Extracellular levels of TNF were higher in abacavir-stimulated whole blood cultures of the abacavir-hypersensitive individual compared with those of the abacavir-tolerant control. • TNF levels were attenuated when CD8 T cells were depleted, compared with undepleted or CD4 T cell-depleted cultures.
- 19. DISCUSSION • Recombinant haplotype mapping was used to confirm a strong genetic association between the 57.1 AH and definite abacavir hypersensitivity, with further evidence that the concurrence of the HLA-B*5701 allele and a haplotypic variant of the Hsp70- Hom allele represents a highly predictive marker of susceptibility. • Patients with a higher CD8 T cell count (850 cells) at the time of exposure to abacavir have an increased risk of developing hypersensitivity. • Lack of sufficient sensitivity when immunological response was measured for rechallenging a patient with abacavir in cases where a previous hypersensitivity reaction is suspected.
- 20. Discussion • Abacavir or its metabolites may be involved in the haptenation of endogenous peptides and subsequent presentation of ‘‘altered self’’ in the context of HLA-B*5701, thus inducing vigorous T cell responses. • Hsp70 plays a direct role in the selection of HLA-B*5701-restricted peptide substrates that are potentially haptenated through an abacavir-dependent mechanism.
- 21. Conclusion • The HLA-B*5701 and Hsp70- Hom M493T alleles as highly predictive genetic markers of susceptibility to abacavir hypersensitivity. • These findings have significant implications in the clinical management of abacavir exposed HIV-infected patients. • Also, it elucidate basic pathophysiological mechanisms underlying this and other idiosyncratic drug hypersensitivity reactions.